DIANT Pharma develops continuous processing technology for nanoparticle drug products and vaccines.
DIANT Pharma develops continuous processing technology for nanoparticle drug products and vaccines. They utilize a proprietary and continuous ethanol-injection system to form nanoparticles with controlled particle sizes at high flow rates, providing pharmaceutical companies with a continuous drug encapsulation technique to achieve their goals and high encapsulation processes.Founded in 2019, DIANT offers technology that is robust and reliable from R&D to manufacturing over a product’s lifespan.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 9, 2022 | Grant | $256K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |